Results for
""Aminosalicylic Acids""[mesh_terms]

Aminosalicylates.

Volker Gross

Digestive diseases (Basel, Switzerland) 2012;30(1):92-9

Optimizing conventional therapy for inflammatory bowel disease.

Russell Cohen, Marc Schwartz

Current gastroenterology reports 2009;10(6):585-90

Medical therapy for ulcerative colitis 2004.

Stephen B Hanauer

Gastroenterology 2004;126(6):1582-92

Treatment of inflammatory bowel disease: safety and tolerability issues.

Stephen B Hanauer, Fernando Navarro

The American journal of gastroenterology 2004;98(12 Suppl):S18-23

Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.

E F Stange

Alimentary pharmacology & therapeutics 2007;24 Suppl 3():64-7

The safety of treatment options for pediatric Crohn's disease.

Victoria Grossi, Jeffrey S Hyams

Expert opinion on drug safety 2017;15(10):1383-90

Safety of balsalazide therapy in the treatment of inflammatory bowel disease.

Danial E Baker

Reviews in gastroenterological disorders 2005;5(3):135-41

Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.

Christopher Ma, Leonardo Guizzetti, Lauren E Cipriano, Claire E Parker, Tran M Nguyen, James C Gregor, Nilesh Chande, Brian G Feagan, Vipul Jairath

Alimentary pharmacology & therapeutics 2020;49(4):364-374

An update on the medical treatment of Crohn's disease.

G Valentini, L Guidi, M Costanzo, M Ciarniello, I De Vitis, E Capristo, G Fedeli

Panminerva medica 2003;45(1):15-22

Objectives and outcomes in the conventional treatment of pediatric Crohn's disease.

H A Büller

Journal of pediatric gastroenterology and nutrition 2002;33 Suppl 1():S11-8

Drugs for inflammatory bowel disease.

Treatment guidelines from the Medical Letter 2009;7(85):65-74; quiz 75-6

Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.

Antonio Tursi, Giovanni Brandimarte, Gian Marco Giorgetti, Giacomo Forti, Maria Ester Modeo, Andrea Gigliobianco

Medical science monitor : international medical journal of experimental and clinical research 2005;10(11):PI126-31

Clinical aspects of ulcerative colitis in mainland China.

Jia Ju Zheng

Chinese journal of digestive diseases 2006;7(2):71-5

Update on medical management of inflammatory bowel disease: ulcerative colitis.

S B Hanauer

Reviews in gastroenterological disorders 2002;1(4):169-76

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.

Carmen Cuffari, David Pierce, Bartosz Korczowski, Krzysztof Fyderek, Heather Van Heusen, Stuart Hossack, Hong Wan, Alena Y Z Edwards, Patrick Martin

Drug design, development and therapy 2016;10():593-607